The Smad3/4 adaptor protein ELF is emerging as a potent regulator of tumorigenesis by its ability to effect TGF-beta tumor suppressor function. However, to date the role of the TGF-beta pathway at specific stages in gastrointestinal (Gl) tumor development such as metaplasia, dysplasia and carcinoma remains poorly delineated, particularly in conjunction with activation of oncogenic pathways. We previously found that deletion of ELF results in a dramatic and spontaneous formation of liver and gastrointestinal (Gl) cancers, with a splice site mutation in elf exon 15 in 11% of human Gl cancer cell lines tested so far. A surprising and serendipitous recent discovery by us is that elf'and elf^/SmadS^'mice develop visceromegaly and multiple Gl cancers (70% of mice), including metastatic pancreatic, hepatocellular, intestinal adenocarcinomas and others spontaneously, providing compelling evidence as a mouse model of Beckwith-Wiedemann syndrome (BWS), a hereditary human cancer syndrome. In addition, 90% of elf''' /Smad4*/~ mice develop gastric cancer, 20% develop colonic adenomas, and ELF expression is lost in human gastric cancer as well as Dukes B1 adenomas indicating a role for ELF in suppression of early human gastrointestinal cancer. Molecular profiling of the tumors in these mice and human Gl cancers demonstrate markedly high levels of cell cycle regulators that include CDK4, cyclin D1 and PRAJA an ELF/Smad3 specific E3 ligase. Interestingly, SmadS has recently been shown to be a CDK4 substrate, yet Smad3 mutant mice do not develop cancers. Thus, activated CDK4 and PRAJA associate with ELF with or without Smad3 and most likely exert their oncogenic activity through suppression ofELF/SmadS.
Our AIMS are to: 1. Determine a functional interaction between ELF, SmadS, and CDK4, and the effect of loss elf, SmadS or Smad4 on CDK4 enzyme activity, towards testing CDK4 inhibitors from project 4, Vitamin D analogs from project 2, as well as developing new therapaeutics targeted allosterically at CDK4 -ELF-Smad3 interaction. 2. Investigate the molecular basis for the differential effects of PRAJA on ELF and SmadS towards generating new inhibitors targeted at PRAJA. 3. Test whether ELF is mutated in BWS, and potentially whether loss of ELF in combination with PRAJA, CDK4, Smad3, Smad4,TBRII, TERT and c-Myc (the latter two from project 3) represent new specific molecular markers for early tumor detection/ treatment response of hepatocellular, gastric and pancreatic cancers. Results from this study promise to yield important new therapeutics and will be a first step toward the goal of individualized cancer treatment based on the functional molecular characteristics of these lethal tumors.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-O)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas MD Anderson Cancer Center
United States
Zip Code
Sun, Hongcheng; Tang, Huamei; Xie, Dacheng et al. (2016) Krüppel-like Factor 4 Blocks Hepatocellular Carcinoma Dedifferentiation and Progression through Activation of Hepatocyte Nuclear Factor-6. Clin Cancer Res 22:502-12
Yan, Jun; Mitra, Abhisek; Hu, Jiemiao et al. (2016) Interleukin-30 (IL27p28) alleviates experimental sepsis by modulating cytokine profile in NKT cells. J Hepatol 64:1128-36
Perumal, Deepak; Kuo, Pei-Yu; Leshchenko, Violetta V et al. (2016) Dual Targeting of CDK4 and ARK5 Using a Novel Kinase Inhibitor ON123300 Exerts Potent Anticancer Activity against Multiple Myeloma. Cancer Res 76:1225-36
Chen, Jian; Shukla, Vivek; Farci, Patrizia et al. (2016) Loss of the TGF-β Effector β2SP Promotes Genomic Instability. Hepatology :
Divakar, S K A; Ramana Reddy, M V; Cosenza, S C et al. (2016) Dual inhibition of CDK4/Rb and PI3K/AKT/mTOR pathways by ON123300 induces synthetic lethality in mantle cell lymphomas. Leukemia 30:86-93
Chen, Jian; Raju, Gottumukkala S; Jogunoori, Wilma et al. (2016) Mutational Profiles Reveal an Aberrant TGF-β-CEA Regulated Pathway in Colon Adenomas. PLoS One 11:e0153933
Katz, L H; Likhter, M; Jogunoori, W et al. (2016) TGF-β signaling in liver and gastrointestinal cancers. Cancer Lett 379:166-72
Chen, Jian; Yao, Zhi-Xing; Chen, Jiun-Sheng et al. (2016) TGF-β/β2-spectrin/CTCF-regulated tumor suppression in human stem cell disorder Beckwith-Wiedemann syndrome. J Clin Invest 126:527-42
Chen, Jian; Katz, Lior H; Muñoz, Nina M et al. (2016) Vitamin D Deficiency Promotes Liver Tumor Growth in Transforming Growth Factor-β/Smad3-Deficient Mice Through Wnt and Toll-like Receptor 7 Pathway Modulation. Sci Rep 6:30217
Mitra, Abhisek; Mishra, Lopa; Li, Shulin (2015) EMT, CTCs and CSCs in tumor relapse and drug-resistance. Oncotarget 6:10697-711

Showing the most recent 10 out of 123 publications